



Zeltia presents Xylazel Aire Sano, a paint that is suitable for healthcare environments which can help reduce the incidence and cost of hospital-acquired infections

- This new product helps prevent pathogens from multiplying on painted walls at hospitals
- It contains silver, a broad-spectrum antimicrobial agent whose activity has been proven against a large variety of pathogens
- All of the properties of this new product in the Xylazel Aire Sano range are supported by standardized tests; as a result, it is the only paint on the Spanish market endorsed by the Spanish Society of Preventive Medicine, Public Health and Hygiene (SEMPSPH)
- According to the SEMPSPH, there are over 300,000 cases of contagion caused by infectious agents in hospitals
- The incidence of hospital-acquired infections is an excellent marker of patient safety and hospital quality

Madrid, 19 June 2013. According to the Spanish Society of Preventive Medicine, Public Health and Hygiene (SEMPSPH), there are over 300,000 cases of contagion caused by infectious agents in hospitals. "*Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Enterococcus faecalis*, *Aspergillus niger* and *Escherichia coli* (*E. coli*) are the five pathogens responsible for the main hospital-acquired infections contracted by patients", said Dr. Jesus Davila, SEMPSPH treasurer, at the press conference for the presentation of Xylazel Air Sano, a paint suitable for healthcare environments. These infections "can lengthen patients' hospital stays and/or cause complications in their underlying conditions that can even be fatal," he added.

In order to help reduce the incidence of hospital-acquired infections in Spain, Grupo Zeltia's chemical subsidiary Xylazel has launched a paint suitable for healthcare environments, which "helps prevent pathogens from multiplying on painted walls in hospitals", said René Petit, head of Technical Service and Development for Xylazel. In addition to having the main characteristics of an indoor paint, he also highlighted "the innovation in terms of contributing to the improvement of health and hygiene conditions required of hospitals." The paint "will contribute significantly to reducing the high cost associated with treating hospital-acquired infections."

All of the properties of this new product in the Xylazel Aire Sano range are supported by standardized tests; as a result, it is the only paint on the Spanish market endorsed by the Spanish Society of Preventive Medicine, Public Health and Hygiene (SEMPSPH).

In addition to providing antibacterial protection, the paint is stable and resistant to the disinfectants commonly used in healthcare settings. "It contains





silver, a broad-spectrum antimicrobial agent whose activity has been proven against a large variety of pathogens", said José Ramón Álvarez, head of R&D, Quality and Control at Xylazel. "It has a proven, powerful and long-lasting antibacterial effect while being clean and harmless to other living beings", he added. "It was tested in accordance with the JIS Z 2801 standard by an accredited independent laboratory".

In the Spanish market "there have been similar paints to the one we are presenting today, although not with the qualities we consider especially important for people who spend lengthy periods in healthcare settings: minimum indoor emissions and a low hazard level", he added. Xylazel Air Sano's paint suitable for healthcare environments "is highly resistant to the cleaning agents and disinfectants commonly used in the health field. We also tested its reaction to fire. It has a B-s1, d0 rating, which means that it makes a negligible contribution to fire development, has very low smoke production and produces no droplets/particles. " The paint can also be used in rooms where food is handled and special hygienic conditions are required, such as kitchens or public dining halls.

Epine 2011 Study

The incidence of hospital-acquired infections is an excellent marker of patient safety and hospital quality. Controlling infections is currently one of the few actions that saves the Spanish healthcare system money while also increasing quality. According to the Epine 2011 study, 6.3% of patients in Spain contracted an infection during hospital stays in the last year, i.e. the lowest rate in the last two decades. A total of 287 hospitals and 61,222 patients throughout Spain participated in the study. Earlier surveys registered higher rates: 8.5% in 1990, 7.8% in 1991 and 7.3% in 1992; however, infection frequency has declined slightly in recent years, stabilising between 6.5% and 6.7%.

About Xylazel:

Xylazel, S.A., a wholly-owned Grupo Zeltia subsidiary, was founded in 1975 and is based at the Las Gándaras industrial estate in Porriño (Pontevedra). Xylazel manufactures and sells paints and varnishes and is specialized in protective and decorative wood and metal products for the DIY, professional and industrial segments. It is a sector leader in wood and metal protectors, and a pioneer in Spain in developing a culture of wood protection. Xylazel is an acknowledged specialist in the markets where it operates and its innovative products are known for their high quality and high added value. The Xylazel brand offers a broad range of highly reputable protection products. It is certified to the ISO 9001 and 14001 standards by BUREAU VERITAS.

About SEMPSPH:

SEMPSPH is an association of doctors specialised in preventive medicine and public health, nurses, and other healthcare professionals. Its objectives include theoretical and practical research in preventive medicine, public health and hygiene and the relationship with medicine and social sciences, prevention of hospital-acquired infections and hospital hygiene.

About Zeltia:

Zeltia S.A. is a world-leading biopharmaceutical company specialised in the development of marine-based drugs for use in oncology. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Genómica, Spain's leading molecular diagnostics company based on DNA analysis; and Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi).





For more information +34 91 444 45 00

This note is also available on the Zeltia web site: www.zeltia.com and on the Xylazel web: www.xylazel.com

